Physician profile
Kara D Williamson
NPI 1700549466
$2,780.72
in general payments reported to CMS, 2019-2025
28 companies · $851 in 2025
The $851 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $977 · 2024: $838 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $682.69 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $360.12 | 2022-2025 | Lifevest |
| Atricure, INC. | $285.96 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| E.R. Squibb & Sons, L.L.C. | $195.73 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $188.55 | 2022-2025 | |
| Daiichi Sankyo INC. | $131.96 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $96.08 | 2024-2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $95.61 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $83.88 | 2022-2023 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $76.64 | 2023 | Arcalyst |
| Novo Nordisk INC | $69.46 | 2023-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $67.45 | 2024-2025 | Inspire |
| Genzyme Corporation | $49.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.54 | 2023 | Jardiance |
| Boston Scientific Corporation | $44.90 | 2023-2024 | Watchman Flx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $37.57 | 2023-2025 | Amvuttra |
| Heartflow, INC. | $37.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.27 | 2022-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $28.64 | 2023 | Evkeeza |
| Cvrx, INC. | $27.94 | 2024 | Barostim Neo System |
| Baxter Healthcare | $21.48 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $19.00 | 2025 | |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | Verquvo |
| Daxor Corporation | $16.91 | 2025 | Bva-100 |
| Edwards Lifesciences Corporation | $16.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.14 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 | |
| Altathera Pharmaceuticals LLC | $12.51 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.